All Posts

We are thrilled to announce that our groundbreaking targeted radionuclide administrative platform, designed for optimized treatment efficiency and the absence of side effects, has been awarded both the Gold Medal and the Organizer's Choice at the International Invention Innovation Competition (iCAN) 2025 in Canada. This prestigious event, recognized globally as a premier platform for inventors, highlights innovations that address critical challenges in various fields. Our tea

Lutetium-177 DOTATATE PRRT—a standard treatment for advanced neuroendocrine tumors—often causes severe gastrointestinal side effects (nausea, vomiting, diarrhea), likely due to co-infusion with kidney-protective amino acids. Our Patented Solution A novel administration platform that safely delivers Lutetium-177 DOTATATE/DOTATOC PRRT, reducing side effects while maintaining efficacy. Proven in real-world use with 20+ patients. Our invention has already obtained Hong Kong SAR,

L’Ord’invent Limited (an InnoHK@HKU spin-off) and ZERO Biotech Limited have won a gold medal at The International Exhibition of Inventions Geneva 2025 for their breakthrough platform improving the administration of Lutetium-177 DOTATOC therapy (PRRT) for neuroendocrine tumors (NETs). Best in Precision and Least in Side Effects This innovative system enhances precision in delivering targeted radiotherapy, minimizing side effects and improving patient outcomes. Already used to